OXFORD, UK, June 30th, 2015
PharmaVentures is pleased to announce that it has acted as advisor to CM Technology Oy (CMT) on its divestment of certain assets to Yokogawa Electric Corporation (Yokogawa). The assets relate to CMT’s world leading capabilities in cellular imaging and analysis.
This transaction is the latest in a series of successful global deals in the life science research tools sector for PharmaVentures’ clients.
Fintan Walton, CEO, PharmaVentures, commented: “PharmaVentures is delighted to have delivered a successful and valuable outcome for our client in a sector where deal activity is bouyant.”
Adrian Dawkes, VP, PharmaVentures, who was lead advisor added: “Cellular imaging and analysis technologies are increasingly important in areas such as regenerative medicine and stem cell technology. Japan is leading the way in many aspects of this research and Yokogawa is therefore an ideal home for CMT’s technologies”.
Over the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions covering licensing, merger, acquisition, divestment and joint venture activities for companies world-wide.
– ends –